Refractory Chronic Lymphocytic Leukemia (CLL) – Drugs In Development, 2024

Powered by

Unlock hidden opportunities in the Pharmaceuticals industry

$2000
Buy Report

Published: June 05, 2024 Report Code: GDGMDHC23041IDB-L5

Select Item

Empower your strategies with our Refractory Chronic Lymphocytic Leukemia (CLL) – Drugs In Development, 2024 report and make more profitable business decisions.

Refractory chronic lymphocytic leukemia (CLL) signifies resistance to standard treatments or rapid relapse following initial therapy. This form of blood and bone marrow cancer presents a formidable challenge, as conventional chemotherapy and targeted approaches may prove ineffective. Managing refractory CLL involves exploring novel agents, immunotherapy, and participation in clinical trials to identify alternative treatment avenues. Tailoring therapy to the unique characteristics of the CLL cells and the patient’s overall health is crucial. Prognosis varies, highlighting the need for ongoing research to develop more efficacious treatments and improve outcomes for individuals grappling with refractory CLL.

The Refractory Chronic Lymphocytic Leukemia (CLL) drugs in development market research report provide comprehensive information on the therapeutics under development for Refractory Chronic Lymphocytic Leukemia (CLL), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Refractory Chronic Lymphocytic Leukemia (CLL) and features dormant and discontinued products.

Note:

* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.

* Certain sections in the report may be removed or altered based on the availability and relevance of data.

Quick View – Refractory Chronic Lymphocytic Leukemia (CLL)
Key Targets
· B Lymphocyte Antigen CD19; Tyrosine Protein Kinase BTK; B Lymphocyte Antigen CD20; Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Delta Isoform; Apoptosis Regulator Bcl 2; B Cell Receptor CD22; CD3 ; Inactive Tyrosine Protein Kinase Transmembrane Receptor ROR1; Cyclin Dependent Kinase 9; and Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Gamma Isoform
Key Mechanisms of Action
· Tyrosine Protein Kinase BTK Inhibitor; Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Delta Isoform Inhibitor; Apoptosis Regulator Bcl 2 Inhibitor; CD3 Agonist; Cyclin Dependent Kinase 9 Inhibitor; Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Gamma Isoform Inhibitor; Protein Cereblon Activator; B Lymphocyte Antigen CD20 Inhibitor; B Lymphocyte Antigen CD19 Inhibitor; and Inactive Tyrosine Protein Kinase Transmembrane Receptor ROR1 Inhibitor
Key Routes of Administration
· Oral; Intravenous; Parenteral; Subcutaneous; Intravenous Drip; Intralesional; Topical; Intraperitoneal; Inhalational; and Intrathecal
Key Molecule Types
· Small Molecule; Gene-Modified Cell Therapy; Monoclonal Antibody; Cell Therapy; Monoclonal Antibody Conjugated; Recombinant Protein; Antibody; Blood Derivative; Antisense RNAi Oligonucleotide; and Synthetic Peptide
Major Companies
· Gilead Sciences Inc; BeiGene Ltd; Bristol-Myers Squibb Co; AbbVie Inc; F. Hoffmann-La Roche Ltd; InnoCare Pharma Ltd; Johnson & Johnson; Novartis AG; Nurix Therapeutics Inc; and Merck & Co Inc

Scope

  • Therapeutics in Development: Covering 137 molecules, with 127 developed by companies and the rest by universities/institutes.

  • Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.

  • Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.

  • Development History: Access the complete research and development history.

  • Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.

Reasons to Buy

  • Holistic insights: Understand the broad spectrum of Refractory Chronic Lymphocytic Leukemia (CLL) therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.

  • Pipeline Exploration: Explore the detailed Refractory Chronic Lymphocytic Leukemia (CLL) pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.

  • Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Refractory Chronic Lymphocytic Leukemia (CLL) treatments for adaptable decision-making.

  • Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.

Key Players

AbbVie Inc
Accutar Biotechnology Inc
Acerta Pharma BV
Adlai Nortye Biopharma Co Ltd
Alloplex Biotherapeutics Inc
Aptose Biosciences Inc
Artiva Biotherapeutics Inc
Ascentage Pharma Group International
AstraZeneca Plc
Athenex Inc
Autolus Therapeutics Plc
AVM Biotechnology LLC
BeiGene Ltd
Beijing Jingda Biotechnology Co Ltd
Bio-Path Holdings Inc
Biomea Fusion Inc
Boryung Pharmaceutical Co Ltd
Bristol-Myers Squibb Co
CARGO Therapeutics Inc
Case Comprehensive Cancer Center
Catapult Therapeutics BV
Chengdu Hyperway Pharmaceutical Co Ltd
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Chimeric Therapeutics Ltd
Chongqing Precision Biotech Co Ltd
CoImmune Inc
Cyclacel Pharmaceuticals Inc
CytoCares Shanghai Inc
Eli Lilly and Co
Evopoint Bioscience Co Ltd
F. Hoffmann-La Roche Ltd
Fate Therapeutics Inc
Galapagos NV
Genentech USA Inc
GenFleet Therapeutics (Shanghai) Inc
Genmab AS
Gilead Sciences Inc
GSK plc
Guangdong East Sunshine Pharmaceutical Co Ltd
Guangzhou BeBetter Medicine Technology Co Ltd
Haisco Pharmaceutical Group Co Ltd
Hangzhou Zenshine Pharmaceuticals Co Ltd
Hebei Senlang Biotechnology Co Ltd
Heidelberg University Hospital
Hospital Israelita Albert Einstein
Hutchison MediPharma Ltd
IDP Discovery Pharma SL
IGM Biosciences Inc
ImmPACT Bio USA Inc
ImmuneOnco Biopharmaceuticals (Shanghai) Co Ltd
Incyte Corp
InnoCare Pharma Ltd
Jiangsu Maidu Drug Research and Development Co Ltd
Johnson & Johnson
Kartos Therapeutics Inc
Karyopharm Therapeutics Inc
Kecellitics Biotech Co Ltd
Lantern Pharma Inc
Lanzhou Institute of Biological Products Co Ltd
Massachusetts General Hospital
Mayo Clinic
Medical College of Wisconsin
MEI Pharma Inc
Merck & Co Inc
Miltenyi Biomedicine GmbH
Minghui Pharmaceutical (Shanghai) Co Ltd
MingSight Pharmaceuticals Inc
MorphoSys AG
Mustang Bio Inc
Nanjing Sanhome Pharmaceutical Co Ltd
National Cancer Institute US
Newave Pharmaceutical Inc
Nkarta Inc
NovalGen Ltd
Novartis AG
Nurix Therapeutics Inc
Octapharma AG
Ohio State University Comprehensive Cancer Center
Oncternal Therapeutics
Ono Pharmaceutical Co Ltd
Pfizer Inc
Precigen Inc
Precision Biosciences Inc
Prelude Therapeutics Inc
Rhizen Pharmaceuticals SA
Sana Biotechnology Inc
SELLAS Life Sciences Group Inc
Shanghai Simnova Biotechnology Co Ltd
SIRPant Immunotherapeutics Inc
Sorrento Therapeutics Inc
Suzhou Fundamenta Therapeutics Co Ltd
Suzhou JiSheng Pharmaceutical Co Ltd
Synthekine Inc
Systimmune Inc
Takara Bio Inc
Takeda Pharmaceutical Co Ltd
Telios Pharma Inc
TG Therapeutics Inc
TransThera Sciences (Nanjing) Inc
UNC Lineberger Comprehensive Cancer Center
UTC Therapeutics Inc
Wuhan Bio-Raid Biotechnology Co Ltd
Xencor Inc
Yakult Honsha Co Ltd
Zhejiang Borui Biopharmaceutical Co Ltd
Zhejiang DTRM Biopharma LLC
Zhejiang Longchuan Biomedical Technology Co Ltd
Zhejiang University School of Medicine Hospital 1

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Overview

Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Drugs Under Development by Companies

Drugs under Development by Universities/Institutes

Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Companies Involved in Therapeutic Development

Drug Profiles

Dormant Projects

Discontinued Drugs

Product Development Milestones

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Table

List of Tables

Number of Drugs under Development, 2024

Number of Drugs under Development by Companies, 2024

Number of Drugs under Development by Universities/Institutes, 2024

Drugs under Development by Companies, 2024

Drugs under Development by Universities/Institutes, 2024

Number of Drugs by Stage and Target, 2024

Number of Drugs by Stage and Mechanism of Action, 2024

Number of Drugs by Stage and Route of Administration, 2024

Number of Drugs by Stage and Molecule Type, 2024

Dormant Projects, 2024

Discontinued Drugs, 2024

Figures

List of Figures

Number of Drugs under Development, 2024

Number of Drugs under Development by Companies, 2024

Number of Drugs under Development by Universities/Institutes, 2024

Number of Drugs by Top 10 Targets, 2024

Number of Drugs by Stage and Top 10 Targets, 2024

Number of Drugs by Top 10 Mechanism of Actions, 2024

Number of Drugs by Stage and Top 10 Mechanism of Actions, 2024

Number of Drugs by Top 10 Routes of Administration, 2024

Number of Drugs by Stage and Top 10 Routes of Administration, 2024

Number of Drugs by Top 10 Molecule Types, 2024

Number of Drugs by Stage and Top 10 Molecule Types, 2024

Frequently asked questions

Currency USD
$2,000

Can be used by individual purchaser only

Most Popular
$4,000

Can be shared by unlimited users within one corporate location e.g. a regional office

$6,000

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Add to Basket

Undecided about purchasing this report?

Enquire Before Buying

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

See what our customers are saying
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

 Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

 Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

 Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

 Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

 Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

 Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

 Senior Account Manager, TSYS

Related reports

View more Refractory Chronic Lymphocytic Leukemia (CLL) reports
Pharmaceuticals
New
Reflux Esophagitis (Gastroesophageal Reflux Disease): Market View, Current and Future…
$3,495 | June 2026
Pharmaceuticals
New
IgA Nephropathy (Berger’s Disease): Market View, Current and Future Competitive…
$3,495 | June 2026
Pharmaceuticals
New
Hepatocellular Carcinoma (HCC): Epidemiology Report and Forecast to 2035
$9,995 | June 2026
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Refractory Chronic Lymphocytic Leukemia (CLL) – Drugs In Development, 2024 in real time.

  • Access a live Refractory Chronic Lymphocytic Leukemia (CLL) – Drugs In Development, 2024 dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.
Tell me more